<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>Selected repurposed drugs that have been suggested/discussed for the treatment of COVID-19 and considerations for patients with liver disease or after liver transplantation.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Drug</th>
    <th>Mechanism of action, rationale for COVID-19</th>
    <th>Considerations for patients with liver diseases or after liver transplantation</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Remdesivir</td>
    <td>
     <list list-type="simple" id="ulist0065">
      <list-item id="u0195">
       <label>•</label>
       <p id="p0365">NUC/viral RNA polymerase inhibitor (completed phase III for Ebola treatment)</p>
      </list-item>
      <list-item id="u0200">
       <label>•</label>
       <p id="p0370">Inhibits SARS-CoV-2 
        <italic>in vitro</italic>
        <xref rid="bib24" ref-type="bibr">
         <sup>24</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0205">
       <label>•</label>
       <p id="p0375">Case reports with COVID-19
        <xref rid="bib26" ref-type="bibr">
         <sup>26</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0070">
      <list-item id="u0210">
       <label>•</label>
       <p id="p0380">No relevant drug-interactions expected
        <xref rid="bib34" ref-type="bibr">
         <sup>34</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0215">
       <label>•</label>
       <p id="p0385">No experience in liver cirrhosis but a NUC might be safer than other drug classes based on experience with NUCs in chronic hepatitis B and C</p>
      </list-item>
      <list-item id="u0220">
       <label>•</label>
       <p id="p0390">Liver toxicity (↑ALT) possible</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Chloroquine/Hydroxychloroquine
     <xref rid="bib35" ref-type="bibr">
      <sup>35</sup>
     </xref> ± azithromycin
    </td>
    <td>
     <list list-type="simple" id="ulist0075">
      <list-item id="u0225">
       <label>•</label>
       <p id="p0395">Interference with the cellular receptor ACE2
        <xref rid="bib24" ref-type="bibr">
         <sup>24</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0230">
       <label>•</label>
       <p id="p0400">Endosomal acidification fusion inhibitor</p>
      </list-item>
      <list-item id="u0235">
       <label>•</label>
       <p id="p0405">Generally used for treatment of malaria and amoebiasis</p>
      </list-item>
      <list-item id="u0240">
       <label>•</label>
       <p id="p0410">
        <italic>In vitro</italic> and 
        <italic>in vivo</italic> data
        <xref rid="bib32" ref-type="bibr">
         <sup>32</sup>
        </xref>
        <sup>,</sup>
        <xref rid="bib36" ref-type="bibr">
         <sup>36</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0080">
      <list-item id="u0245">
       <label>•</label>
       <p id="p0415">Exclude G6PD deficiency before application</p>
      </list-item>
      <list-item id="u0250">
       <label>•</label>
       <p id="p0420">Drug-interactions with immunosuppressive drugs: close monitoring of drug level is required for cyclosporine, tacrolimus, sirolimus, everolimus
        <xref rid="bib34" ref-type="bibr">
         <sup>34</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0255">
       <label>•</label>
       <p id="p0425">Hydroxychloroquine therapy has not been associated with ALT abnormalities and is an extremely rare cause of clinically apparent acute liver injury (LiverTox).</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Lopinavir/ritonavir</td>
    <td>
     <list list-type="simple" id="ulist0085">
      <list-item id="u0260">
       <label>•</label>
       <p id="p0430">Lopinavir/ritonavir are approved PIs for HIV</p>
      </list-item>
      <list-item id="u0265">
       <label>•</label>
       <p id="p0435">
        <italic>In vitro</italic> data, experience in patients with SARS, case reports with COVID-19
        <xref rid="bib37" ref-type="bibr">
         <sup>37</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0270">
       <label>•</label>
       <p id="p0440">No proven efficacy 
        <italic>in vivo</italic> in severe COVID-19
        <xref rid="bib28" ref-type="bibr">
         <sup>28</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0275">
       <label>•</label>
       <p id="p0445">Many centres have discontinued its use</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0090">
      <list-item id="u0280">
       <label>•</label>
       <p id="p0450">Known and well-studied drug-interactions with immunosuppressive drugs. mTOR inhibitors (sirolimus, everolimus) should not be co-administered, close monitoring of drug level are required for calcineurin-inhibitors (cyclosporin, tacrolimus)
        <xref rid="bib34" ref-type="bibr">
         <sup>34</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0285">
       <label>•</label>
       <p id="p0455">Data for patients with liver cirrhosis exist
        <xref rid="bib38" ref-type="bibr">
         <sup>38</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0290">
       <label>•</label>
       <p id="p0460">The risk of lopinavir-associated hepatotoxicity in patients with very advanced liver disease is low</p>
      </list-item>
      <list-item id="u0295">
       <label>•</label>
       <p id="p0465">Based on experience with PIs in HCV, patients with decompensated cirrhosis should not be treated</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Tocilizumab</td>
    <td>
     <list list-type="simple" id="ulist0095">
      <list-item id="u0300">
       <label>•</label>
       <p id="p0470">Humanised mAb targeting interleukin-6 receptor</p>
      </list-item>
      <list-item id="u0305">
       <label>•</label>
       <p id="p0475">Treat cytokine release syndrome observed in COVID-19
        <xref rid="bib7" ref-type="bibr">
         <sup>7</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0100">
      <list-item id="u0310">
       <label>•</label>
       <p id="p0480">ALT elevations are frequent but clinically apparent liver injury with jaundice seem to be rare
        <xref rid="bib39" ref-type="bibr">
         <sup>39</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0315">
       <label>•</label>
       <p id="p0485">Patients with decompensated cirrhosis should not be treated</p>
      </list-item>
      <list-item id="u0320">
       <label>•</label>
       <p id="p0490">Consider risk of HBV reactivation
        <xref rid="bib40" ref-type="bibr">
         <sup>40</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Methylprednisolone (steroids)</td>
    <td>
     <list list-type="simple" id="ulist0105">
      <list-item id="u0325">
       <label>•</label>
       <p id="p0495">Corticosteroids bind nuclear receptors to dampen proinflammatory cytokines</p>
      </list-item>
      <list-item id="u0330">
       <label>•</label>
       <p id="p0500">Mostly used in patients with septic shock</p>
      </list-item>
      <list-item id="u0335">
       <label>•</label>
       <p id="p0505">Currently NOT recommended by WHO
        <xref rid="bib41" ref-type="bibr">
         <sup>41</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0110">
      <list-item id="u0340">
       <label>•</label>
       <p id="p0510">The risk of other infections (
        <italic>e.g.</italic> SBP) and viral shedding may increase in patents with decompensated liver cirrhosis
       </p>
      </list-item>
      <list-item id="u0345">
       <label>•</label>
       <p id="p0515">Consider antimicrobial prophylaxis</p>
      </list-item>
      <list-item id="u0350">
       <label>•</label>
       <p id="p0520">Consider risk of HBV reactivation</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Convalescent plasma</td>
    <td>
     <list list-type="simple" id="ulist0115">
      <list-item id="u0355">
       <label>•</label>
       <p id="p0525">Case reports with COVID-19
        <xref rid="bib42" ref-type="bibr">
         <sup>42</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0120">
      <list-item id="u0360">
       <label>•</label>
       <p id="p0530">No experience in patients with chronic liver disease</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Umifenovir (Arbidol)
     <xref rid="tbl1fnlowast" ref-type="table-fn">∗</xref>
    </td>
    <td>
     <list list-type="simple" id="ulist0125">
      <list-item id="u0365">
       <label>•</label>
       <p id="p0535">May inhibit viral entry into target cells and stimulate the immune response, used to treat influenza in some countries
        <xref rid="bib31" ref-type="bibr">
         <sup>31</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0130">
      <list-item id="u0370">
       <label>•</label>
       <p id="p0540">Possible drug interactions between arbidol and CYP3A4 inhibitors and inducers
        <xref rid="bib43" ref-type="bibr">
         <sup>43</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0375">
       <label>•</label>
       <p id="p0545">Potentially metabolised in liver and intestines in humans. Caution in patients with liver cirrhosis</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Favipiravir/favilavir
     <xref rid="tbl1fnlowast" ref-type="table-fn">∗</xref>
    </td>
    <td>
     <list list-type="simple" id="ulist0135">
      <list-item id="u0380">
       <label>•</label>
       <p id="p0550">Guanine analogue, RNA-dependent RNA polymerase (RdRp)- inhibitor, approved for influenza in Japan</p>
      </list-item>
      <list-item id="u0385">
       <label>•</label>
       <p id="p0555">Preliminary results from a study with 80 COVID-19 patients
        <xref rid="bib31" ref-type="bibr">
         <sup>31</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0140">
      <list-item id="u0390">
       <label>•</label>
       <p id="p0560">Metabolised by aldehyde oxidase and xanthine oxidase. CYP450 isoenzymes are not involved in the metabolism</p>
      </list-item>
      <list-item id="u0395">
       <label>•</label>
       <p id="p0565">Elevation of ALT and AST possible.</p>
      </list-item>
      <list-item id="u0400">
       <label>•</label>
       <p id="p0570">No data in cirrhosis available</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Sofosbuvir
     <xref rid="tbl1fnlowast" ref-type="table-fn">∗</xref>
     <break/>maybe combination with ribavirin
    </td>
    <td>
     <list list-type="simple" id="ulist0145">
      <list-item id="u0405">
       <label>•</label>
       <p id="p0575">Nucleotide analogue, RdRp-inhibitor</p>
      </list-item>
      <list-item id="u0410">
       <label>•</label>
       <p id="p0580">Approved for treatment of chronic hepatitis C</p>
      </list-item>
      <list-item id="u0415">
       <label>•</label>
       <p id="p0585">
        <italic>In vitro</italic> data show binding to SARS-CoV-2 RdRp
        <xref rid="bib44" ref-type="bibr">
         <sup>44</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0150">
      <list-item id="u0420">
       <label>•</label>
       <p id="p0590">Good experience in patients with chronic hepatitis C including patients with decompensated cirrhosis</p>
      </list-item>
      <list-item id="u0425">
       <label>•</label>
       <p id="p0595">For drug-interaction details see
        <xref rid="bib45" ref-type="bibr">
         <sup>45</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0430">
       <label>•</label>
       <p id="p0600">Ribavirin may cause severe haemolytic anaemia</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Baricitinib
     <xref rid="tbl1fnlowast" ref-type="table-fn">∗</xref>
    </td>
    <td>
     <list list-type="simple" id="ulist0155">
      <list-item id="u0435">
       <label>•</label>
       <p id="p0605">Janus kinase inhibitor, might interrupt endocytosis of the virus and intracellular assembly of virus particles
        <xref rid="bib46" ref-type="bibr">
         <sup>46</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0440">
       <label>•</label>
       <p id="p0610">Could affect both inflammation and cellular viral entry</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0160">
      <list-item id="u0445">
       <label>•</label>
       <p id="p0615">Associated with transient and usually mild elevations of ALT
        <xref rid="bib47" ref-type="bibr">
         <sup>47</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0450">
       <label>•</label>
       <p id="p0620">Patients with decompensated cirrhosis should not be treated</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Camostat
     <xref rid="tbl1fnlowast" ref-type="table-fn">∗</xref>
    </td>
    <td>
     <list list-type="simple" id="ulist0165">
      <list-item id="u0455">
       <label>•</label>
       <p id="p0625">Blocks serine protease TMPRSS2 
        <italic>in vitro</italic> which is required for S protein priming
        <xref rid="bib48" ref-type="bibr">
         <sup>48</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0460">
       <label>•</label>
       <p id="p0630">Licensed in Japan for treatment of chronic pancreatitis</p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0170">
      <list-item id="u0465">
       <label>•</label>
       <p id="p0635">Patients with chronic viral hepatitis and cirrhosis are excluded from clinical trial for chronic pancreatitis.
        <xref rid="bib49" ref-type="bibr">
         <sup>49</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0470">
       <label>•</label>
       <p id="p0640">Drug-interactions unknown</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Emapalumab
     <xref rid="tbl1fnlowast" ref-type="table-fn">∗</xref>
    </td>
    <td>
     <list list-type="simple" id="ulist0175">
      <list-item id="u0475">
       <label>•</label>
       <p id="p0645">mAb targeting interferon-gamma</p>
      </list-item>
      <list-item id="u0480">
       <label>•</label>
       <p id="p0650">Treat cytokine release syndrome observed in COVID-19
        <xref rid="bib7" ref-type="bibr">
         <sup>7</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0485">
       <label>•</label>
       <p id="p0655">Approved for haemophagocytic lymphohistiocytosis</p>
      </list-item>
      <list-item id="u0490">
       <label>•</label>
       <p id="p0660">Clinical trial for COVID-19 planned
        <xref rid="bib50" ref-type="bibr">
         <sup>50</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0180">
      <list-item id="u0495">
       <label>•</label>
       <p id="p0665">Associated with mild and transient ALT elevations typically arising a few weeks after start of treatment</p>
      </list-item>
      <list-item id="u0500">
       <label>•</label>
       <p id="p0670">Risk of reactivation of tuberculosis, pneumocystis jirovecii, herpes zoster</p>
      </list-item>
      <list-item id="u0505">
       <label>•</label>
       <p id="p0675">Risk of HBV reactivation may be lower</p>
      </list-item>
     </list>
    </td>
   </tr>
   <tr>
    <td>Anakinra
     <xref rid="tbl1fnlowast" ref-type="table-fn">∗</xref>
    </td>
    <td>
     <list list-type="simple" id="ulist0185">
      <list-item id="u0510">
       <label>•</label>
       <p id="p0680">Interleukin 1 receptor antagonist</p>
      </list-item>
      <list-item id="u0515">
       <label>•</label>
       <p id="p0685">Clinical trial for COVID-19 planned
        <xref rid="bib50" ref-type="bibr">
         <sup>50</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td>
     <list list-type="simple" id="ulist0190">
      <list-item id="u0520">
       <label>•</label>
       <p id="p0690">Minimal hepatic metabolism</p>
      </list-item>
     </list>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="tspara0015">
   <p>This list is not intended to give treatment recommendations. The evidence to use these drugs is low. Multiple RCTs for the above-mentioned drugs and some other drugs are ongoing in patients with SARS-CoV-2 infection.</p>
  </fn>
  <fn id="tspara0020">
   <p>ACE2, angiotensin-converting enzyme 2; ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID-19, coronavirus disease 2019; NUC, nucleoside analogue; PIs, protease inhibitors; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tbl1fnlowast">
   <label>∗</label>
   <p id="ntpara0010">These drugs are listed to include the most frequently discussed agents for COVID-19. These drugs may lack clinical efficacy, and some have been considered based on 
    <italic>in vitro</italic> observations or their mode of action.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
